Lenrispodun

DB15039InvestigationalSmall molecule

ITI-214 is under investigation in clinical trial NCT03489772 (Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement).

Mechanism: Pharmacologically active on Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B, Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A, and Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C
Curator reviewed
Formula / weight: C₂₉H₂₆FN₇O · 507.573 g/mol (avg)
Code names: ITI-214

Resolves to

Compound

Structure

InChIKeyBBIPVJCGIASXJB-PKTZIBPZSA-NSMILESCN1C2=N[C@@H]3CCC[C@@H]3N2C2=NN(CC3=CC=C(C=C3)C3=NC(F)=CC=C3)C(NC3=CC=CC=C3)=C2C1=O

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lenrispodun, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.